Figure 4: Comparison of in vivo cannabimimetic pharmacological effects.
From: Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity
HU210 dose-dependently elicited catalepsy (a), antinociception (b) and hypothermia (c), but HU308, HU910 and JWH133 lacked appreciable pharmacological effects in each assay. Whereas pretreatment with SR141716A (3 mg kg−1) attenuated the magnitude of cataleptic (d), antinociceptive (e) and hypothermic (f) effects of HU210 (1.7 mg kg−1), HU910 did not significantly reduce HU210-induced catalepsy (g), antinociception (h) or hypothermia (i). Filled symbols denote significance versus the respective vehicle injection for each drug (a–c). ****P<0.0001 HU210 versus respective pretreatment (PTx) (Holm-Sidak’s test). ^^^^P<0.0001 versus vehicle/HU210 (Holm-Sidak’s test). Sample sizes=8 mice/group (a–c) and 6 mice/group (d–i). All values reflect mean ± s.e.m.
